Non-demyelinating, reversible conduction failure in Fisher syndrome and related disorders

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 9, 2012, Pages 941-948

  Umapathi, Thirugnanam ^a   Tan, Eyok Yian ^a   Kokubun, Norito ^b   Verma, Kamal ^a   Yuki, Nobuhiro ^c  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ABDUCENS NERVE PARALYSIS; ADULT; AREFLEXIA; ARTICLE; ARTIFICIAL VENTILATION; BICKERSTAFF BRAINSTEM ENCEPHALITIS; BULBAR PARALYSIS; CLINICAL ARTICLE; DEMYELINATION; ENCEPHALITIS; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HYPOREFLEXIA; LIMB WEAKNESS; MALE; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NERVE POTENTIAL; NONDEMYELINATING REVERSIBLE CONDUCTION FAILURE; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMYELINIZATION; SENSORY NERVE;

ACTION POTENTIALS; ADULT; AUTOANTIBODIES; ENCEPHALITIS; FEMALE; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; MILLER FISHER SYNDROME; NEURAL CONDUCTION; OPHTHALMOPLEGIA;

EID: 84864810700     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303079     Document Type: Article

References (44)

1. Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998;44:202-8. (Pubitemid 28374108)
2. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67. (Pubitemid 46597169)
3. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996;25 :33-51.
4. Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012; 233:534-42.
5. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-6. (Pubitemid 32336323)
6. Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9.
7. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993;118:83-7. (Pubitemid 23269971)
8. Ito M, Matsuno K, Sakumoto Y, et al. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82 :294-9.
9. Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann Neurol 1996;39:668-72.
10. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001;70:50-5. (Pubitemid 32096120)
11. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64:1605-11. (Pubitemid 40617699)
12. Kuwabara S, Ogawara K, Misawa S, et al. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome? Neurology 2004;63:529-33. (Pubitemid 39031386)
13. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998;44:780-8. (Pubitemid 28516049)
14. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
15. Bickerstaff ER. Brain-stem encephalitis: further observations on a grave syndrome with benign prognosis. Br Med J 1957;1:1384-7.
16. Dehaene I, Martin JJ, Geens K, et al. Guillain-Barré syndrome with ophthalmoplegia: clinicopathologic study of the central and peripheral nervous systems, including the oculomotor nerves. Neurology 1986;36:851-4. (Pubitemid 16056231)
17. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003;126:2279-90. (Pubitemid 37432371)
18. Richter RB. The ataxic form of polyradiculoneuritis (Landry-Guillain- Barré syndrome): clinical and pathologic observations. J Neuropathol Exp Neurol 1962;21:171-84.
19. Uncini A, Manzoli C, Notturno F, et al. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157-63.
20. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008;255:674-82.
21. Capasso M, Notturno F, Mazoli C, et al. Involvement of sensory fibers in axonal subtypes of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2011;82:664-70.
22. Olney RK. Guidelines in electrodiagnostic medicine: consensus criteria for the diagnosis of partial conduction block. Muscle Nerve Suppl 1999;8:S225-9. (Pubitemid 29374200)
23. Kuwabara S, Ogawara K, Mizobuchi K, et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry 2000;68:191-5. (Pubitemid 30245842)
24. Sauron B, Bouche P, Cathala HP, et al. Miller Fisher syndrome: clinical and electrophysiologic evidence of peripheral origin in 10 cases. Neurology 1984;34:953-6. (Pubitemid 14076464)
25. Jamal GA, Ballantyne JP. The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome): a serial multimodal neurophysiological study. Brain 1988;111:95-114.
26. Scelsa SN, Herskovitz S. Miller Fisher syndrome: axonal, demyelinating or both? Electromyogr Clin Neurophysiol 2000;40:497-502. (Pubitemid 32041174)
27. Shahrizaila N, Goh KJ, Kokubun N, et al. Serial nerve conduction studies provide insight into the pathophysiology of Guillain-Barré and Fisher syndromes. J Neurol Sci 2011;309:26-30.
28. Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987;37:1493-8. (Pubitemid 17132330)
29. Funakoshi K, Kuwabara S, Odaka M, et al. Clinical predictors of mechanical ventilation in Fisher/Guillain-Barré overlap syndrome. J Neurol Neurosurg Psychiatry 2009;80:60-4.
30. Guiloff RJ. Peripheral nerve conduction in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1977;40:801-7. (Pubitemid 8203126)
31. Katsuno M, Ando T, Hakusui S, et al. Motor conduction studies in Miller Fisher syndrome with severe tetraparesis. Muscle Nerve 2002;25:378-82. (Pubitemid 34203214)
32. Rajabally YA, Hassan-Smith G, Notturno F, et al. Motor and sensory conduction failure in overlap of Guillain-Barré and Miller Fisher syndrome: two simultaneous cases. J Neurol Sci 2011;303:35-8.
33. Uncini A, Lugaresi A. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve 1999;22:640-4. (Pubitemid 29214432)
34. Tatsumoto M, Odaka M, Hirata K, et al. Isolated abducens nerve palsy as a regional variant of Guillain-Barré syndrome. J Neurol Sci 2006; 243:35-8.
35. Kuwabara S, Asahina M, Nakajima M, et al. Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 1999; 45:533-6. (Pubitemid 29165824)
36. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40:635-44. (Pubitemid 26357889)
37. Notturno F, Caporale CM, Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve 2008;37:265-8. (Pubitemid 351214176)
38. Pan CL, Yuki N, Koga M, et al. Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody. Neurology 2001;57:1316-18. (Pubitemid 32947397)
39. Chiba A, Kusunoki S, Obata H, et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32-6. (Pubitemid 27055743)
40. Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 2005;65:1376-81. (Pubitemid 41552764)
41. Gilbert M, Karwaski MF, Bernatchez S, et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni: biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 2002;277:327-37. (Pubitemid 34952062)
42. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17. (Pubitemid 23318855)
43. Liu JX, Willison HJ, Pedrosa-Domellof F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009;50 :3226-32.
44. Kimoto K, Koga M, Odaka M, et al. Relationship of bacterial strains to clinical syndromes of Campylobacter -associated neuropathies. Neurology 2006;67:1837-43. (Pubitemid 44900763)